Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi’s Toujeo Is Approved, Now The Hard Part: Commercialization

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi’s next-generation long-acting insulin will compete against an entrenched rival, the company’s own Lantus – a challenging proposition for any drug marketer, especially in the increasingly cost-conscious diabetes sector.

You may also be interested in...

Sanofi, Long-Time Leader In Diabetes, Is Exiting Diabetes Research

The company's decision to exit diabetes research is not necessarily surprising given the development and commercial challenges in the therapeutic area, but it's not insignificant either.

Sanofi Board Forces CEO Chris Viehbacher to Resign Amid Lantus Woes

Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.

GSK Reveals Big Changes As 2015 Growth Prospects Fizzle

GlaxoSmithKline’s all important asthma drug, Advair, has taken a hit and the impact is bleeding out to the rest of the business. As GSK braces for a challenging 2015, the company announced a £1 billion cost savings program and plans to explore an IPO for its HIV subsidiary ViiV Healthcare.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts